$ 369.84
Key Takeaways
Risk factor
Very high price volatility
Profitability factor
Greatly overvalued vs peers
About
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops...
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. Specifically, the stock is neutral on EV/EBITDA, overpriced on P/FC.
Target Price
The average target price of MDGL is 438 and suggests 18% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increas
